Session » ACR Convergence 2022
-
Abstract Number: L01
Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
-
Abstract Number: L03
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
-
Abstract Number: L04
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
-
Abstract Number: L08
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
-
Abstract Number: L09
Impact on Access to Methotrexate in the Post-Roe Era
-
Abstract Number: L10
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
-
Abstract Number: L11
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
-
Abstract Number: L12
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
-
Abstract Number: L13
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
-
Abstract Number: L15
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
-
Abstract Number: L17
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
-
Abstract Number: PP01
Why Communication Is the Most Important Thing in Healthcare
-
Abstract Number: PP02
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
-
Abstract Number: PP03
To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
-
Abstract Number: PP04
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
-
Abstract Number: PP05
From Practical Tips to Heartfelt Encouragement: How Social Media Can Improve Quality of Life with Rheumatic Disease
-
Abstract Number: PP06
Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
-
Abstract Number: PP07
Remissions and Vigilance
-
Abstract Number: PP08
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
-
Abstract Number: PP09
A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
-
Abstract Number: PP10
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
-
Abstract Number: PP11
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
-
Abstract Number: PP12
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
-
Abstract Number: PP13
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
-
Abstract Number: PP14
The Use of Social Support as Treatment
-
Abstract Number: PP15
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
-
Abstract Number: PP16
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
-
Abstract Number: PP17
Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA
-
Abstract Number: PP18
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
-
Abstract Number: PP19
Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment
-
Abstract Number: PP20
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
-
Abstract Number: PP21
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
-
Abstract Number: PP22
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
-
Abstract Number: PP23
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
-
Abstract Number: PP24
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
-
Abstract Number: PP25
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
-
Abstract Number: PP26
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
-
Abstract Number: 0002
Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy
-
Abstract Number: 0003
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
-
Abstract Number: 0004
mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
-
Abstract Number: 0005
The Rheumatology Access Expansion (RAE) Initiative: Improving Rheumatoid Arthritis Care on Navajo Nation Through Primary Care Provider Education
-
Abstract Number: 0006
Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
-
Abstract Number: 0008
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
-
Abstract Number: 0009
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
-
Abstract Number: 0010
The Inflammation Induced by Monosodium Urate and Calcium Pyrophosphate Crystals Depends on Osmolarity and Aquaporin Channels
-
Abstract Number: 0011
B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice
-
Abstract Number: 0012
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
-
Abstract Number: 0013
Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome
-
Abstract Number: 0014
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
-
Abstract Number: 0015
Differential Antigen Binding of Closely Related Monoclonal ACPA
-
Abstract Number: 0016
Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE
-
Abstract Number: 0017
Intra-articular Injection of Bacterial DNA Amplified from Human OA Patient Cartilage Worsens OA Outcomes in Mice
-
Abstract Number: 0018
Longitudinal Development of Cartilage Microbial DNA Profiles Following Oral Microbiome Inoculation
-
Abstract Number: 0019
Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
-
Abstract Number: 0020
Redoxosomes Mediate a Feed-forward Loop of Cartilage Matrix Destruction Through α5β1 Integrin Signaling in Response to a Fibronectin Matrikine
-
Abstract Number: 0021
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
-
Abstract Number: 0022
Beneficial Structural Impact of Liraglutide, a GLP1 Receptor Agonist, in Three Inflammatory and Post-traumatic OA Animal Models
-
Abstract Number: 0023
New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature
-
Abstract Number: 0024
Exposure to Pollutants with Endocrine Disrupting Properties Is Associated with Early Cartilage Defects and Chondrocyte Inflammatory and Oxidative Activation
-
Abstract Number: 0025
Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells
-
Abstract Number: 0026
Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage
-
Abstract Number: 0027
Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis
-
Abstract Number: 0028
Microenvironmental Stiffness Modulates Macrophage Responsiveness and Communication with Mesenchymal Stem Cells
-
Abstract Number: 0029
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
-
Abstract Number: 0030
Fluidic Shear Stress Reduces TNFα-mediated Cartilage Damage in a 3D Model of Degenerative Joint Disease
-
Abstract Number: 0031
Discovery of GSTT1 Gene That Promotes Osteogenic Differentiation of Adipose Stem Cells
-
Abstract Number: 0032
Defective Chaperone-mediated Autophagy Is a Hallmark of Joint Disease in Patients with Knee Osteoarthritis
-
Abstract Number: 0033
Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells
-
Abstract Number: 0034
Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis
-
Abstract Number: 0035
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
-
Abstract Number: 0037
Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity
-
Abstract Number: 0038
STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
-
Abstract Number: 0039
Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases
-
Abstract Number: 0040
Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity
-
Abstract Number: 0041
Modeling Juvenile Dermatomyositis with Engineered Human Skeletal Muscle: Effects of Type I Interferonβ and Janus Kinase Inhibitors
-
Abstract Number: 0042
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
-
Abstract Number: 0043
Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
-
Abstract Number: 0045
Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
-
Abstract Number: 0046
Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion
-
Abstract Number: 0047
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
-
Abstract Number: 0049
IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment
-
Abstract Number: 0050
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
-
Abstract Number: 0051
Identification of a Transcription Factor That Drives Polarization Toward Tissue-destructive Fibroblasts in Arthritis
-
Abstract Number: 0052
Elucidating Androgen Effects on Focal Erosions in TNF-Induced Inflammatory Arthritis
-
Abstract Number: 0053
Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis
-
Abstract Number: 0054
MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts
-
Abstract Number: 0055
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
-
Abstract Number: 0056
Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
-
Abstract Number: 0057
Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
-
Abstract Number: 0058
Health System Improvement in Inpatient ANA and Serologic Test Utilization
-
Abstract Number: 0059
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0060
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
-
Abstract Number: 0061
Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
-
Abstract Number: 0062
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
-
Abstract Number: 0063
Implementability of a SLE Medication Adherence Intervention
-
Abstract Number: 0064
Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
-
Abstract Number: 0065
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
-
Abstract Number: 0066
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
-
Abstract Number: 0067
Cost Per Responder in RA Patients Failing First Line Treatment
-
Abstract Number: 0068
Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
-
Abstract Number: 0069
Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
-
Abstract Number: 0070
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
-
Abstract Number: 0071
Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis
-
Abstract Number: 0072
Geographical Patterns of Healthcare Utilization Among RA and OA Patients
-
Abstract Number: 0073
Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
-
Abstract Number: 0074
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
-
Abstract Number: 0075
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
-
Abstract Number: 0076
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
-
Abstract Number: 0077
Rheumatoid Arthritis – Are We Getting to Target?
-
Abstract Number: 0078
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems
-
Abstract Number: 0079
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
-
Abstract Number: 0080
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
-
Abstract Number: 0081
Impact of the COVID-19 Pandemic on Rheumatology Services in a Universal Healthcare Setting in Canada: A Population-based Study
-
Abstract Number: 0082
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
-
Abstract Number: 0083
COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
-
Abstract Number: 0084
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
-
Abstract Number: 0085
Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet?
-
Abstract Number: 0086
Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis
-
Abstract Number: 0087
Does Limited English Proficiency Lead to Additional Health Inequity in Medically Vulnerable Populations in Outpatient Rheumatology?
-
Abstract Number: 0088
Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review
-
Abstract Number: 0089
Racial Disparities in Rheumatology Clinical Trials
-
Abstract Number: 0090
Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
-
Abstract Number: 0091
Association of Area-Level Heat and Social Vulnerability with Recurrent Hospitalizations Among Individuals with Rheumatic Conditions
-
Abstract Number: 0093
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
-
Abstract Number: 0094
Black Patients Are Less Satisfied with the Hospital Experience After Primary Hip and Knee Arthroplasty
-
Abstract Number: 0095
Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
-
Abstract Number: 0096
Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
-
Abstract Number: 0097
Sex and Race/ethnicity Differences in Knee Symptoms, Function, and Radiographic Features: Preliminary Descriptive Data from the Johnston County Health Study
-
Abstract Number: 0098
Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0099
Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
-
Abstract Number: 0100
COVID Vaccinations in Patients with Rheumatologic Diseases- perspectives and Disparities in a Safety-net Tertiary Care Hospital in Memphis, Tennessee
-
Abstract Number: 0101
Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status
-
Abstract Number: 0102
Impact of Racial Implicit Bias on Juvenile Idiopathic Arthritis Patients’ Treatment Recommendations
-
Abstract Number: 0103
Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
-
Abstract Number: 0104
Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumatology-Focused Journals
-
Abstract Number: 0105
Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
-
Abstract Number: 0106
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
-
Abstract Number: 0107
Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil
-
Abstract Number: 0108
Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders
-
Abstract Number: 0109
The Impact of Marginalization on Health Outcomes in Childhood-onset Systemic Lupus Erythematosus
-
Abstract Number: 0110
Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
-
Abstract Number: 0111
Gender Equity in the Asia Pacific: Comparison of Indian and Philippines Rheumatology Conferences
-
Abstract Number: 0112
What Drives Racial Disparities in Gout in the USA? – Population-Based, Sex-Specific, Casual Mediation Analysis
-
Abstract Number: 0113
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
-
Abstract Number: 0114
Addressing Healthcare Disparities Through Implementation of a Medical Student-Based Patient Navigator Program
-
Abstract Number: 0115
Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff
-
Abstract Number: 0116
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
-
Abstract Number: 0117
Disparities in Prescription Medications Among Myositis Patients in a Large Urban Medical Center
-
Abstract Number: 0118
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
-
Abstract Number: 0119
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
-
Abstract Number: 0120
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
-
Abstract Number: 0121
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
-
Abstract Number: 0122
Documentation of Social Determinants of Health Among Individuals with Systemic Rheumatic and Musculoskeletal Diseases
-
Abstract Number: 0123
Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases
-
Abstract Number: 0124
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
-
Abstract Number: 0125
Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab
-
Abstract Number: 0126
Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
-
Abstract Number: 0128
Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
-
Abstract Number: 0130
Three Chinese Pedigrees of A20 Haploinsufficiency
-
Abstract Number: 0131
Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
-
Abstract Number: 0132
Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre
-
Abstract Number: 0133
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
-
Abstract Number: 0134
Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
-
Abstract Number: 0135
Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review
-
Abstract Number: 0136
Sarcoidosis Incidence After mTOR Inhibitor Treatment
-
Abstract Number: 0137
Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
-
Abstract Number: 0138
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
-
Abstract Number: 0139
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
-
Abstract Number: 0140
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
-
Abstract Number: 0141
Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
-
Abstract Number: 0142
A Systemic Autoinflammatory Syndrome Caused by NEMO Exon 5 Skipping
-
Abstract Number: 0143
National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
-
Abstract Number: 0144
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
-
Abstract Number: 0145
Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
-
Abstract Number: 0146
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
-
Abstract Number: 0147
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
-
Abstract Number: 0148
Dysferlin Associated Autoinflammatory Disease Causing Systemic Inflammation and Sterile Lung Abcesses Through Impaired Efferocytosis
-
Abstract Number: 0149
Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations
-
Abstract Number: 0150
Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
-
Abstract Number: 0151
Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
-
Abstract Number: 0152
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
-
Abstract Number: 0153
Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
-
Abstract Number: 0154
Anti-SMN Autoantibodies in Mixed Connective Tissue Disease Are Associated with a Scleromyositis Phenotype
-
Abstract Number: 0155
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
-
Abstract Number: 0156
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
-
Abstract Number: 0157
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
-
Abstract Number: 0158
Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis
-
Abstract Number: 0159
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
-
Abstract Number: 0160
Sarcopenia in Myositis Patients: A Marker of Muscle Damage Associated with Myositis Severity and Disability
-
Abstract Number: 0161
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
-
Abstract Number: 0162
Clinical Features Associated with the Presence of anti-SSA/Ro60 Antibodies in anti-Jo-1 Antibody-positive Myositis
-
Abstract Number: 0163
Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic
-
Abstract Number: 0164
Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies
-
Abstract Number: 0165
Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
-
Abstract Number: 0166
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
-
Abstract Number: 0167
Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases
-
Abstract Number: 0168
Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)
-
Abstract Number: 0169
Comparison of Diagnostic Criteria Sets in Diagnosing Antisynthetase Syndrome
-
Abstract Number: 0170
Minimal Clinically Important Difference in Myositis Response Criteria
-
Abstract Number: 0171
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
-
Abstract Number: 0172
Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study
-
Abstract Number: 0173
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
-
Abstract Number: 0174
Intra-rater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis
-
Abstract Number: 0175
Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention
-
Abstract Number: 0176
Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis
-
Abstract Number: 0178
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
-
Abstract Number: 0179
Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies
-
Abstract Number: 0180
Alterations of Nutritional Status in Patients with Idiopathic Inflammatory Myopathies and Their Association with Disease-related Features
-
Abstract Number: 0181
Patient Perspective of Unique Support and Education Needs of Latinx/Latino(a)/Hispanic Rheumatoid Arthritis Patients: Implications for a Culturally Tailored and Disease Specific Intervention
-
Abstract Number: 0182
Newly Diagnosed with Inflammatory Arthritis. Development of a Complex Self-management Intervention
-
Abstract Number: 0183
LupusConnect™: A 24/7 Online Lupus Support Community
-
Abstract Number: 0184
Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
-
Abstract Number: 0185
Empowered2work: Development and Delivery of a Multi-faceted Peer-coaching Workshop Focusing on Health Promotion and Ergonomic Issues in the Workplace
-
Abstract Number: 0186
Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
-
Abstract Number: 0187
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
-
Abstract Number: 0188
COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
-
Abstract Number: 0189
Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
-
Abstract Number: 0190
Effect of Shared Decision-making on Trust in Physician in the Clinical Practice of Systemic Lupus Erythematosus: The TRUMP2-SLE Study
-
Abstract Number: 0191
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
-
Abstract Number: 0192
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
-
Abstract Number: 0193
Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study
-
Abstract Number: 0194
A Survey of Patients with Ehlers Danlos Syndrome and Their Interest in Multidisciplinary Care
-
Abstract Number: 0195
Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
-
Abstract Number: 0196
The Impact of Barometric Pressure Waves on Connective Tissue Disorders
-
Abstract Number: 0197
Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars
-
Abstract Number: 0198
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
-
Abstract Number: 0199
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
-
Abstract Number: 0200
Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?
-
Abstract Number: 0201
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
-
Abstract Number: 0202
Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
-
Abstract Number: 0203
Feasibility and Acceptability of Integrating Patient Reported Outcomes Within Routine Care of Rheumatoid Arthritis
-
Abstract Number: 0204
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
-
Abstract Number: 0205
Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
-
Abstract Number: 0206
Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada
-
Abstract Number: 0207
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
-
Abstract Number: 0208
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
-
Abstract Number: 0209
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
-
Abstract Number: 0210
Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
-
Abstract Number: 0211
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
-
Abstract Number: 0212
Managing Psoriatic Arthritis: Patients’ Views and Attitudes to Using an Online Wellness Program
-
Abstract Number: 0213
“The Best Part Is Feeling Like I Could Go out There and Maybe Really Help Somebody”: Training Peer Coaches to Deliver the Moving Well Total Knee Replacement Telephone-Based Coaching Program
-
Abstract Number: 0214
The Structured Curriculum Development Significantly Increased the Pediatric Residents’ Competency and Confidence During a 4-week Pediatric Rheumatology Rotation
-
Abstract Number: 0215
Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
-
Abstract Number: 0216
The Rejected Manuscripts: Its Quality, Its Fate, and Empirical-based Suggestions for Improvement
-
Abstract Number: 0217
Where Are the Reporting Guidelines in Rheumatology? An Analysis of Their Use in over 850 Published Manuscripts
-
Abstract Number: 0219
COVID-19 Impact on Second Year Medical Students Experience with Interactive Patient Encounters as a Supplement to Teaching the Skin and Rheumatology Course
-
Abstract Number: 0220
Social Media Use in Academic Rheumatology
-
Abstract Number: 0221
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
-
Abstract Number: 0222
Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula
-
Abstract Number: 0223
Assessment During Rheumatology Fellowship After the Reforms in the French National Medical Curriculum: Has Anything Changed?
-
Abstract Number: 0224
Developing and Evaluating a Rheumatology Nurse Competency Framework to Guide Professional Development and Career Progression
-
Abstract Number: 0225
A Transitions Retreat: Preparing Rheumatology Fellows for Career Planning and the Scholarly Phase of Training
-
Abstract Number: 0226
Linguistics Biases in Letters of Recommendation Written for Rheumatology Fellowship Applicants
-
Abstract Number: 0227
The Rheumatology Workforce: Analyzing Geographic and Temporal Variations Among the Rheumatology Physician Workforce in the United States
-
Abstract Number: 0228
Are We Choosing Wisely? Results of a Survey of Internal Medicine Residents in a Single Center
-
Abstract Number: 0229
The Effect of Interactive E-learning on Resident’s Practical Performance in Musculoskeletal Ultrasound- a Randomized Study
-
Abstract Number: 0230
Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers
-
Abstract Number: 0231
Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
-
Abstract Number: 0232
RheumMadness: Early Learner Experience and Impact
-
Abstract Number: 0233
Monoarthritis Virtual Teaching Module for Rheumatology Learners
-
Abstract Number: 0234
Scouting Reports as a Social Constructivist Teaching Tool in RheumMadness
-
Abstract Number: 0235
Procedure-Based Musculoskeletal Ultrasound Curriculum for Rheumatology Fellows
-
Abstract Number: 0237
Whats Trending? A 12- year Analysis of International Medical Graduates Matching into Rheumatology Fellowship Programs in the United States
-
Abstract Number: 0238
Educational Experience and Engagement in the First Two Years of RheumMadness, an Online Community of Inquiry
-
Abstract Number: 0240
Few and Far Between: Addressing the Pediatric Rheumatology Workforce Gap with a Spotlight on Medicine-pediatrics Residency Trained Rheumatologist Career Paths
-
Abstract Number: 0241
Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
-
Abstract Number: 0242
Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
-
Abstract Number: 0243
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
-
Abstract Number: 0244
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
-
Abstract Number: 0245
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
-
Abstract Number: 0246
Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis
-
Abstract Number: 0247
Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association
-
Abstract Number: 0248
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
-
Abstract Number: 0249
Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
-
Abstract Number: 0250
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
-
Abstract Number: 0251
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
-
Abstract Number: 0252
Mitochondrial Content in Skeletal Muscle of Individuals with Rheumatoid Arthritis Is Associated with Physical Activity Level
-
Abstract Number: 0253
Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
-
Abstract Number: 0254
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
-
Abstract Number: 0255
Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
-
Abstract Number: 0256
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
-
Abstract Number: 0257
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
-
Abstract Number: 0258
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
-
Abstract Number: 0259
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
-
Abstract Number: 0260
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
-
Abstract Number: 0261
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
-
Abstract Number: 0262
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
-
Abstract Number: 0264
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
-
Abstract Number: 0265
In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
-
Abstract Number: 0266
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
-
Abstract Number: 0267
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
-
Abstract Number: 0268
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
-
Abstract Number: 0269
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
-
Abstract Number: 0270
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
-
Abstract Number: 0271
Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
-
Abstract Number: 0272
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
-
Abstract Number: 0273
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
-
Abstract Number: 0274
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
-
Abstract Number: 0275
Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
-
Abstract Number: 0276
Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
-
Abstract Number: 0277
Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
-
Abstract Number: 0278
The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
-
Abstract Number: 0279
Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
-
Abstract Number: 0280
Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
-
Abstract Number: 0281
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
-
Abstract Number: 0282
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
-
Abstract Number: 0284
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
-
Abstract Number: 0285
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
-
Abstract Number: 0286
Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
-
Abstract Number: 0288
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
-
Abstract Number: 0289
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
-
Abstract Number: 0291
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
-
Abstract Number: 0292
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
-
Abstract Number: 0294
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
-
Abstract Number: 0295
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
-
Abstract Number: 0296
Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors
-
Abstract Number: 0297
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
-
Abstract Number: 0298
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
-
Abstract Number: 0299
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
-
Abstract Number: 0300
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
-
Abstract Number: 0302
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
-
Abstract Number: 0303
Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICETM) Database
-
Abstract Number: 0305
Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
-
Abstract Number: 0309
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
-
Abstract Number: 0310
Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
-
Abstract Number: 0311
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
-
Abstract Number: 0312
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
-
Abstract Number: 0314
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
-
Abstract Number: 0315
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
-
Abstract Number: 0316
Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis
-
Abstract Number: 0317
Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression
-
Abstract Number: 0318
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
-
Abstract Number: 0319
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
-
Abstract Number: 0320
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
-
Abstract Number: 0321
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
-
Abstract Number: 0322
Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?
-
Abstract Number: 0323
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
-
Abstract Number: 0324
Comparison of NCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
-
Abstract Number: 0325
Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution
-
Abstract Number: 0326
Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort
-
Abstract Number: 0327
SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus
-
Abstract Number: 0328
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
-
Abstract Number: 0329
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
-
Abstract Number: 0330
Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model
-
Abstract Number: 0331
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
-
Abstract Number: 0333
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
-
Abstract Number: 0334
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
-
Abstract Number: 0335
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
-
Abstract Number: 0336
Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record
-
Abstract Number: 0337
Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
-
Abstract Number: 0338
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
-
Abstract Number: 0339
Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus
-
Abstract Number: 0340
Birth Order Is a Risk Factor for Systemic Lupus Erythematosus
-
Abstract Number: 0341
Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice
-
Abstract Number: 0342
Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements
-
Abstract Number: 0344
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
-
Abstract Number: 0345
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
-
Abstract Number: 0346
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
-
Abstract Number: 0347
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
-
Abstract Number: 0348
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
-
Abstract Number: 0349
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
-
Abstract Number: 0350
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0351
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
-
Abstract Number: 0352
The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
-
Abstract Number: 0353
Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
-
Abstract Number: 0355
Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
-
Abstract Number: 0356
Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
-
Abstract Number: 0357
Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
-
Abstract Number: 0358
Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
-
Abstract Number: 0359
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
-
Abstract Number: 0360
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
-
Abstract Number: 0361
Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
-
Abstract Number: 0362
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
-
Abstract Number: 0363
Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
-
Abstract Number: 0366
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
-
Abstract Number: 0367
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
-
Abstract Number: 0368
Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
-
Abstract Number: 0369
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
-
Abstract Number: 0370
Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
-
Abstract Number: 0372
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
-
Abstract Number: 0373
Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
-
Abstract Number: 0374
The BASDAI Index During Pregnancy
-
Abstract Number: 0375
The Presence of Heel Enthesitis on Physical Exploration Is Associated with Poorer Outcomes After 2 Years of Follow-up in Patients with Radiographic Axial Spondyloarthritis
-
Abstract Number: 0377
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
-
Abstract Number: 0378
Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics
-
Abstract Number: 0379
Physical Activity Is Associated with Physical and Global Function in Patients with Axial Spondyloarthritis, Independent of Disease Activity
-
Abstract Number: 0380
Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort
-
Abstract Number: 0381
Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patients with Axial SpA: Results from ASAS-PerSpA
-
Abstract Number: 0382
Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
-
Abstract Number: 0383
Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA
-
Abstract Number: 0384
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
-
Abstract Number: 0385
T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation
-
Abstract Number: 0386
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
-
Abstract Number: 0387
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
-
Abstract Number: 0388
Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
-
Abstract Number: 0389
Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
-
Abstract Number: 0390
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
-
Abstract Number: 0391
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
-
Abstract Number: 0392
Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
-
Abstract Number: 0393
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
-
Abstract Number: 0394
In Radiographic Axial Spondyloarthritis Spinal Mobility Measures Correlate Well with the Whole Spine CT Syndesmophyte Score (CTSS)
-
Abstract Number: 0395
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
-
Abstract Number: 0396
Validity of Syndesmophyte Detection on Low Dose Computed Tomography in Patients with Radiographic Axial Spondyloarthritis
-
Abstract Number: 0397
Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis
-
Abstract Number: 0398
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
-
Abstract Number: 0399
ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis
-
Abstract Number: 0400
Is There Any Influence of Gender on the Sociodemographic and Clinical Characteristics of Psoriatic Arthrithis?
-
Abstract Number: 0401
Direct to Patient Screening of Psoriatic Arthritis: Clinical Findings and Outcomes of Patient-Driven Rheumatology Referrals
-
Abstract Number: 0402
Opioid Use and Healthcare Utilization in Adults with PsA and AS
-
Abstract Number: 0403
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
-
Abstract Number: 0404
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
-
Abstract Number: 0405
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
-
Abstract Number: 0406
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
-
Abstract Number: 0407
Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
-
Abstract Number: 0408
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
-
Abstract Number: 0409
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
-
Abstract Number: 0412
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
-
Abstract Number: 0414
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
-
Abstract Number: 0415
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
-
Abstract Number: 0416
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
-
Abstract Number: 0417
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
-
Abstract Number: 0418
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
-
Abstract Number: 0419
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
-
Abstract Number: 0420
What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain
-
Abstract Number: 0421
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
-
Abstract Number: 0422
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
-
Abstract Number: 0423
Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
-
Abstract Number: 0424
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
-
Abstract Number: 0425
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
-
Abstract Number: 0426
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
-
Abstract Number: 0427
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
-
Abstract Number: 0428
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
-
Abstract Number: 0429
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
-
Abstract Number: 0430
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
-
Abstract Number: 0431
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
-
Abstract Number: 0432
Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
-
Abstract Number: 0433
Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset
-
Abstract Number: 0434
Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample
-
Abstract Number: 0435
Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
-
Abstract Number: 0436
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
-
Abstract Number: 0437
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
-
Abstract Number: 0438
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
-
Abstract Number: 0439
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
-
Abstract Number: 0440
COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
-
Abstract Number: 0441
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort
-
Abstract Number: 0442
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
-
Abstract Number: 0443
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
-
Abstract Number: 0444
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
-
Abstract Number: 0445
Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
-
Abstract Number: 0446
The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis
-
Abstract Number: 0447
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
-
Abstract Number: 0448
All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study
-
Abstract Number: 0449
Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
-
Abstract Number: 0450
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
-
Abstract Number: 0451
Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
-
Abstract Number: 0452
Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
-
Abstract Number: 0453
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
-
Abstract Number: 0454
Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients
-
Abstract Number: 0455
Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
-
Abstract Number: 0456
Application of Adult ACR/EULAR 2022 Classification Criteria in Pediatric Vasculitis Patients
-
Abstract Number: 0457
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
-
Abstract Number: 0458
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
-
Abstract Number: 0459
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
-
Abstract Number: 0460
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
-
Abstract Number: 0461
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
-
Abstract Number: 0462
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
-
Abstract Number: 0463
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
-
Abstract Number: 0464
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
-
Abstract Number: 0465
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
-
Abstract Number: 0466
Assessment of Probability Scores to Predict Giant Cell Arteritis
-
Abstract Number: 0467
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
-
Abstract Number: 0468
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
-
Abstract Number: 0469
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
-
Abstract Number: 0470
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
-
Abstract Number: 0471
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
-
Abstract Number: 0472
The Common Carotid Artery in the Ultrasound Evaluation of Giant Cell Arteritis
-
Abstract Number: 0473
Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis
-
Abstract Number: 0474
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
-
Abstract Number: 0475
Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis
-
Abstract Number: 0476
Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High
-
Abstract Number: 0477
Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
-
Abstract Number: 0478
Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR
-
Abstract Number: 0479
A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA
-
Abstract Number: 0480
Treatment of Giant Cell Arteritis Patients with Ultra-short Glucocorticoids and Tocilizumab: Role of Imaging in a Prospective Study
-
Abstract Number: 0481
Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
-
Abstract Number: 0482
Role of miR-146a and miR-146b in Giant Cell Arteritis
-
Abstract Number: 0483
Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
-
Abstract Number: 0484
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
-
Abstract Number: 0485
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
-
Abstract Number: 0486
Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
-
Abstract Number: 0487
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
-
Abstract Number: 0488
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
-
Abstract Number: 0489
Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
-
Abstract Number: 0490
Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study
-
Abstract Number: 0491
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
-
Abstract Number: 0492
Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
-
Abstract Number: 0493
MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center
-
Abstract Number: 0494
Risk for Visual Loss in Patients with Giant Cell Arteritis
-
Abstract Number: 0495
Seasonal Variation in the Incidence of GCA in the UK and Ireland
-
Abstract Number: 0496
Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
-
Abstract Number: 0497
Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis
-
Abstract Number: 0578
Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein
-
Abstract Number: 0579
Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts
-
Abstract Number: 0580
18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis
-
Abstract Number: 0581
Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders
-
Abstract Number: 0582
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
-
Abstract Number: 0583
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
-
Abstract Number: 0584
Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways
-
Abstract Number: 0585
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
-
Abstract Number: 0586
Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse
-
Abstract Number: 0587
Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases
-
Abstract Number: 0588
S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation
-
Abstract Number: 0589
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
-
Abstract Number: 0590
Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling
-
Abstract Number: 0591
Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis
-
Abstract Number: 0592
Autoantibodies Targeting Malondialdehyde-modifications Are Potential Mediators of Inflammation and Bone Loss in RA, Acting via Macrophage and Osteoclast Regulatory Pathways
-
Abstract Number: 0593
A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation
-
Abstract Number: 0594
Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts
-
Abstract Number: 0595
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
-
Abstract Number: 0596
Neutrophil Extracellular Traps (NET) Trigger an Enhanced Pro-inflammatory Response in Macrophage Subpopulations in Rheumatoid Arthritis Patients via the Aryl Hydrocarbon Receptor (AhR) Pathway
-
Abstract Number: 0597
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
-
Abstract Number: 0599
Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
-
Abstract Number: 0600
Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership
-
Abstract Number: 0601
Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
-
Abstract Number: 0603
Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
-
Abstract Number: 0604
Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis
-
Abstract Number: 0605
Citrullinated Peptide-Specific ACPA Are Present in the Female Genital Tract in Premenopausal Women with and Without RA
-
Abstract Number: 0606
Mechanism of Joint-Specific Homeobox D10 Regulation in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
-
Abstract Number: 0607
Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness
-
Abstract Number: 0608
Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis
-
Abstract Number: 0609
Macrophage Response to MAA Modified Fibrinogen in the Presence of Peptidyl Arginine Deiminase Inhibitor
-
Abstract Number: 0610
Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation
-
Abstract Number: 0611
Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis
-
Abstract Number: 0612
Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response
-
Abstract Number: 0613
The Subsets of Synovial Fluid Derived Fibroblasts in Clinical Features of Rheumatoid Arthritis
-
Abstract Number: 0614
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
-
Abstract Number: 0615
Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
-
Abstract Number: 0616
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
-
Abstract Number: 0617
Killer Cell Immunoglobulin Receptor and Class I HLA Genetic Variability in South-eastern Spanish Rheumatoid Arthritis Patients
-
Abstract Number: 0618
Regulation of IgA Secretion Through PAD2-mediated Citrullination of MZB1
-
Abstract Number: 0619
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
-
Abstract Number: 0620
Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo
-
Abstract Number: 0621
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
-
Abstract Number: 0622
Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients
-
Abstract Number: 0623
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
-
Abstract Number: 0624
CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
-
Abstract Number: 0625
Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients
-
Abstract Number: 0626
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
-
Abstract Number: 0627
Spatial Transcriptomic Analysis Reveals Vascular Zonation of Myofibroblasts in Rheumatoid Arthritis Synovium
-
Abstract Number: 0628
A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis
-
Abstract Number: 0629
The Cellular Metabolism of SLE NK Cells Is Primarily Altered at the Level of Mitochondrial Respiration
-
Abstract Number: 0630
Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis
-
Abstract Number: 0631
Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
-
Abstract Number: 0632
Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity
-
Abstract Number: 0633
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
-
Abstract Number: 0634
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
-
Abstract Number: 0635
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
-
Abstract Number: 0636
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
-
Abstract Number: 0637
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
-
Abstract Number: 0638
Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
-
Abstract Number: 0639
Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
-
Abstract Number: 0640
Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
-
Abstract Number: 0641
IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
-
Abstract Number: 0642
SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells
-
Abstract Number: 0643
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
-
Abstract Number: 0644
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
-
Abstract Number: 0645
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
-
Abstract Number: 0646
Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway
-
Abstract Number: 0647
Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes
-
Abstract Number: 0648
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
-
Abstract Number: 0649
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
-
Abstract Number: 0650
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
-
Abstract Number: 0651
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
-
Abstract Number: 0652
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
-
Abstract Number: 0653
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
-
Abstract Number: 0654
Lymphatic Dysfunction and Immune Activation in Lupus
-
Abstract Number: 0655
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
-
Abstract Number: 0656
Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
-
Abstract Number: 0657
DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions
-
Abstract Number: 0658
Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
-
Abstract Number: 0659
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
-
Abstract Number: 0660
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
-
Abstract Number: 0661
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
-
Abstract Number: 0662
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
-
Abstract Number: 0663
Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus
-
Abstract Number: 0664
Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients
-
Abstract Number: 0666
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
-
Abstract Number: 0667
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
-
Abstract Number: 0668
Differential Expression of Interferon Related Genes in SLE Patients of Asian and European Ancestries Abstract
-
Abstract Number: 0669
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
-
Abstract Number: 0670
A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade
-
Abstract Number: 0672
Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome
-
Abstract Number: 0673
Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
-
Abstract Number: 0674
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
-
Abstract Number: 0675
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
-
Abstract Number: 0676
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
-
Abstract Number: 0677
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
-
Abstract Number: 0678
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
-
Abstract Number: 0679
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample
-
Abstract Number: 0680
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
-
Abstract Number: 0681
Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study
-
Abstract Number: 0682
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
-
Abstract Number: 0684
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
-
Abstract Number: 0685
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
-
Abstract Number: 0686
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
-
Abstract Number: 0687
DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients
-
Abstract Number: 0688
Antibodies of the IgA Isotype Target Neutrophil Extracellular Traps in APS
-
Abstract Number: 0689
Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
-
Abstract Number: 0690
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
-
Abstract Number: 0691
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
-
Abstract Number: 0692
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
-
Abstract Number: 0693
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
-
Abstract Number: 0694
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
-
Abstract Number: 0695
Epidemiology of Behçet’s Disease in Northern Spain
-
Abstract Number: 0696
The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
-
Abstract Number: 0697
Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?
-
Abstract Number: 0698
Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women
-
Abstract Number: 0699
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
-
Abstract Number: 0700
Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning
-
Abstract Number: 0702
Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study
-
Abstract Number: 0703
Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
-
Abstract Number: 0704
Clinically Suspect Arthralgia Patients with a Low Educational Attainment Have an Increased Risk to Develop Inflammatory Arthritis
-
Abstract Number: 0705
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
-
Abstract Number: 0706
Association Between Metabolic Syndrome and Knee Pain over 10-13 Years in Middle-Aged Adults
-
Abstract Number: 0707
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
-
Abstract Number: 0708
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
-
Abstract Number: 0709
Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program
-
Abstract Number: 0710
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
-
Abstract Number: 0711
Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study
-
Abstract Number: 0712
Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study
-
Abstract Number: 0713
The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States
-
Abstract Number: 0714
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
-
Abstract Number: 0715
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
-
Abstract Number: 0716
Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic
-
Abstract Number: 0717
Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States
-
Abstract Number: 0718
Biomarkers Predict Worsening of Lumbar Spine Degeneration and Low Back Pain: The Johnston County Osteoarthritis Project
-
Abstract Number: 0719
Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
-
Abstract Number: 0720
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
-
Abstract Number: 0721
Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
-
Abstract Number: 0722
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
-
Abstract Number: 0723
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
-
Abstract Number: 0724
Development of a Global Strategy to Strengthen Health Systems for Prevention and Management of Musculoskeletal Health
-
Abstract Number: 0725
Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit
-
Abstract Number: 0726
Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care
-
Abstract Number: 0727
Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System
-
Abstract Number: 0728
Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery
-
Abstract Number: 0730
Improving Mental Health Services in Children and Adolescents with Systemic Lupus Erythematosus by Establishing a Mental Health Care Navigator
-
Abstract Number: 0731
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
-
Abstract Number: 0732
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
-
Abstract Number: 0734
Comfort Levels and Practice Patterns for Osteoporosis-Related Care Among Persons Living with HIV in Peru: A National Physician Survey
-
Abstract Number: 0735
Facilitators and Barriers to Weekly Monitoring of Disease Activity with Electronic Patient Reported Outcomes: A Focus Group Study of Patients with Inflammatory Arthritis
-
Abstract Number: 0736
Educational Needs Among Health Professionals in Rheumatology: Low Awareness of EULAR Offerings and Unfamiliarity with Course Content as a Major Barrier – a EULAR Funded European Survey
-
Abstract Number: 0737
Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
-
Abstract Number: 0738
Integrated Behavioral Health Services for Patients with Chronic Musculoskeletal Pain: Rheumatology Provider Perspectives
-
Abstract Number: 0739
Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions
-
Abstract Number: 0741
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
-
Abstract Number: 0742
Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial
-
Abstract Number: 0743
Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis
-
Abstract Number: 0744
University of North Carolina and Piedmont Health Collaborative Tele-Rheumatology Project to Optimize Rural Health Specialty Access
-
Abstract Number: 0745
Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System
-
Abstract Number: 0746
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
-
Abstract Number: 0747
Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination
-
Abstract Number: 0748
Mapping Long COVID-19 Patient Journeys for Rheumatic Disease Patients
-
Abstract Number: 0749
Virtual Care in Rheumatology Ambulatory Clinics During the COVID-19 Pandemic: Patient/Family and Healthcare Provider Perspectives and Experiences
-
Abstract Number: 0751
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
-
Abstract Number: 0752
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
-
Abstract Number: 0753
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
-
Abstract Number: 0754
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
-
Abstract Number: 0755
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
-
Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
-
Abstract Number: 0757
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
-
Abstract Number: 0758
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
-
Abstract Number: 0759
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
-
Abstract Number: 0760
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
-
Abstract Number: 0761
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
-
Abstract Number: 0762
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
-
Abstract Number: 0763
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
-
Abstract Number: 0764
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
-
Abstract Number: 0766
CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
-
Abstract Number: 0767
Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
-
Abstract Number: 0768
Reevaluating Clinical Outcomes of Patients on Combination Biologics
-
Abstract Number: 0769
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
-
Abstract Number: 0770
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
-
Abstract Number: 0771
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
-
Abstract Number: 0772
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
-
Abstract Number: 0773
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
-
Abstract Number: 0774
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
-
Abstract Number: 0775
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
-
Abstract Number: 0776
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
-
Abstract Number: 0777
Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
-
Abstract Number: 0778
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
-
Abstract Number: 0779
Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
-
Abstract Number: 0780
B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients
-
Abstract Number: 0781
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
-
Abstract Number: 0782
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
-
Abstract Number: 0783
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
-
Abstract Number: 0784
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
-
Abstract Number: 0785
Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
-
Abstract Number: 0786
Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
-
Abstract Number: 0787
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
-
Abstract Number: 0790
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
-
Abstract Number: 0791
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
-
Abstract Number: 0792
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
-
Abstract Number: 0793
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
-
Abstract Number: 0794
Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases
-
Abstract Number: 0795
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
-
Abstract Number: 0796
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
-
Abstract Number: 0797
Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease
-
Abstract Number: 0798
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
-
Abstract Number: 0799
Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study
-
Abstract Number: 0800
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
-
Abstract Number: 0801
Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
-
Abstract Number: 0802
Is There Any Relationship Between Helicobacter Pylori and Rheumatoid Arthritis?
-
Abstract Number: 0803
Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis
-
Abstract Number: 0804
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
-
Abstract Number: 0805
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
-
Abstract Number: 0806
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
-
Abstract Number: 0807
High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
-
Abstract Number: 0808
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
-
Abstract Number: 0810
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
-
Abstract Number: 0811
Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
-
Abstract Number: 0812
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
-
Abstract Number: 0813
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis
-
Abstract Number: 0814
Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA
-
Abstract Number: 0815
Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
-
Abstract Number: 0816
Increased Risk of Hepatotoxicity with DMARDS in Patients with Previous Liver Toxicity with Isoniazid: Study in a Single University Hospital
-
Abstract Number: 0817
Predictive Severity Factors of COVID-19 in Patients with Rheumatic Immune Mediated Diseases
-
Abstract Number: 0818
NLRP12-associated Autoinflammatory Disease in Chinese Adult Patients: A Single-center Study
-
Abstract Number: 0819
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
-
Abstract Number: 0820
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
-
Abstract Number: 0821
Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model
-
Abstract Number: 0822
Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic
-
Abstract Number: 0823
Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review
-
Abstract Number: 0824
Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
-
Abstract Number: 0825
Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective Study on 43 Consecutive Patients with MAS
-
Abstract Number: 0826
Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database
-
Abstract Number: 0827
Unpublished Clinical Trials of Major Rheumatic Diseases
-
Abstract Number: 0828
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
-
Abstract Number: 0829
Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes
-
Abstract Number: 0830
Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
-
Abstract Number: 0831
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
-
Abstract Number: 0832
Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
-
Abstract Number: 0833
Disability Among Persons with Chronic Severe Back Pain: Results from a Nationally Representative Population Based Sample
-
Abstract Number: 0834
Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain
-
Abstract Number: 0835
Temporal Trends in Prosthetic Joint Infection
-
Abstract Number: 0836
Bone Turnover and Physical Activity Before and After Anterior Cruciate Ligament Reconstruction
-
Abstract Number: 0837
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
-
Abstract Number: 0838
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
-
Abstract Number: 0839
Association of Tibial Acceleration During Walking to Knee Pain and Loading in Adults with Knee Osteoarthritis
-
Abstract Number: 0840
Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
-
Abstract Number: 0841
Relation of PainDETECT to Unpredictable Pain in People with or at Risk of Knee Osteoarthritis
-
Abstract Number: 0842
The Amount of Fluid in the Retrocalcaneal Area Negatively Correlates with Lower Extremity Function
-
Abstract Number: 0843
Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
-
Abstract Number: 0844
Differences in Skin Advanced Glycation End-Products Levels Between Subgroups of Achilles Tendinopathy
-
Abstract Number: 0845
Predictors of Moderate-Vigorous Physical Activity Following a Physical Therapist Led Physical Activity Intervention for Adults with Total Knee Replacement
-
Abstract Number: 0846
Exercise Identity at the Start of Outpatient Physical Therapy Prospectively Predicts Physical Activity at 12-weeks After Total Knee Replacement
-
Abstract Number: 0847
Association of Frontal Plane Trunk Motion During Gait with Abductor Strength, Fatigue, and Physical Activity in Women with Hip Osteoarthritis
-
Abstract Number: 0848
Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease
-
Abstract Number: 0849
The Impact of Diabetes Status on Pain and Disability Following Total Joint Arthroplasty for Hip and Knee Osteoarthritis: Variation by Sex and Body Mass Index
-
Abstract Number: 0850
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
-
Abstract Number: 0851
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
-
Abstract Number: 0852
Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
-
Abstract Number: 0853
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
-
Abstract Number: 0854
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
-
Abstract Number: 0855
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
-
Abstract Number: 0857
Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis
-
Abstract Number: 0858
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
-
Abstract Number: 0859
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
-
Abstract Number: 0860
Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?
-
Abstract Number: 0861
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
-
Abstract Number: 0862
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
-
Abstract Number: 0863
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
-
Abstract Number: 0864
Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
-
Abstract Number: 0865
Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
-
Abstract Number: 0866
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
-
Abstract Number: 0867
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
-
Abstract Number: 0868
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
-
Abstract Number: 0869
Behavioral Health Outcomes and Social Determinants of Health in Children with Juvenile Arthritis Compared to Children with Diabetes and Healthy Children
-
Abstract Number: 0870
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
-
Abstract Number: 0872
Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis
-
Abstract Number: 0873
Celiac-Associated Arthritis: Clinical Features, Treatment, and Outcomes
-
Abstract Number: 0875
Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
-
Abstract Number: 0876
Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
-
Abstract Number: 0877
Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
-
Abstract Number: 0878
A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
-
Abstract Number: 0879
Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
-
Abstract Number: 0880
Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis
-
Abstract Number: 0881
Social Cognitive Correlates of Accelerometer-measured and Self-reported Physical Activity in Persons with Systemic Lupus Erythematosus
-
Abstract Number: 0882
Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
-
Abstract Number: 0883
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
-
Abstract Number: 0884
Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
-
Abstract Number: 0885
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
-
Abstract Number: 0886
Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study
-
Abstract Number: 0889
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
-
Abstract Number: 0891
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
-
Abstract Number: 0892
Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment
-
Abstract Number: 0893
ATP-Binding Cassette G1 Membrane Transporter-mediated Cholesterol Efflux Capacity Influences Coronary Atherosclerosis and Cardiovascular Risk in RA
-
Abstract Number: 0894
DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
-
Abstract Number: 0895
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
-
Abstract Number: 0896
Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
-
Abstract Number: 0897
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
-
Abstract Number: 0898
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
-
Abstract Number: 0899
Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis
-
Abstract Number: 0900
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
-
Abstract Number: 0901
Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life
-
Abstract Number: 0902
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
-
Abstract Number: 0903
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
-
Abstract Number: 0904
Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
-
Abstract Number: 0905
Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry
-
Abstract Number: 0906
Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients
-
Abstract Number: 0907
Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre
-
Abstract Number: 0908
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
-
Abstract Number: 0909
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
-
Abstract Number: 0910
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
-
Abstract Number: 0911
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
-
Abstract Number: 0912
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
-
Abstract Number: 0913
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
-
Abstract Number: 0914
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
-
Abstract Number: 0915
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
-
Abstract Number: 0916
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
-
Abstract Number: 0918
Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
-
Abstract Number: 0919
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
-
Abstract Number: 0921
Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
-
Abstract Number: 0922
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
-
Abstract Number: 0923
Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
-
Abstract Number: 0924
Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
-
Abstract Number: 0925
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
-
Abstract Number: 0926
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
-
Abstract Number: 0927
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
-
Abstract Number: 0928
Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
-
Abstract Number: 0929
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
-
Abstract Number: 0930
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
-
Abstract Number: 0931
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
-
Abstract Number: 0932
Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
-
Abstract Number: 0933
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
-
Abstract Number: 0934
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
-
Abstract Number: 0936
Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
-
Abstract Number: 0937
Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response
-
Abstract Number: 0940
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
-
Abstract Number: 0941
Surveying Adolescents with Rheumatic Disease for At-Risk Behavior
-
Abstract Number: 0942
Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls
-
Abstract Number: 0943
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
-
Abstract Number: 0944
Inconsistent Family Planning Documentation in Women with Interstitial Pneumonia with Autoimmune Features (IPAF)
-
Abstract Number: 0945
Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry
-
Abstract Number: 0946
The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE
-
Abstract Number: 0947
Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases
-
Abstract Number: 0948
Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease
-
Abstract Number: 0949
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience
-
Abstract Number: 0950
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
-
Abstract Number: 0952
Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution
-
Abstract Number: 0953
Increased Risk of Preterm Delivery Phenotypes and Hypertensive Disorders of Pregnancy in First Deliveries of Patients with Systemic Vasculitis
-
Abstract Number: 0954
What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries
-
Abstract Number: 0955
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
-
Abstract Number: 0956
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
-
Abstract Number: 0957
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
-
Abstract Number: 0958
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
-
Abstract Number: 0959
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
-
Abstract Number: 0960
Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0961
The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
-
Abstract Number: 0962
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
-
Abstract Number: 0963
Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy
-
Abstract Number: 0964
High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies
-
Abstract Number: 0965
Pregnancy Outcomes in a Diverse Lupus Cohort
-
Abstract Number: 0966
Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus
-
Abstract Number: 0967
Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus
-
Abstract Number: 0968
Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort
-
Abstract Number: 0969
Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis
-
Abstract Number: 0970
Influence of Sociodemographic and Clinical Features on Ground Reaction Force Variability Among Individuals with Symptomatic Knee Osteoarthritis: A Novel Computational Approach
-
Abstract Number: 0971
Development of a Theory-based Educational Intervention for Fatigue in Systemic Lupus Erythematosus (SLE) Using Human-centered Design Methodology
-
Abstract Number: 0972
Automated Joint Space Width Measurement for Hand Osteoarthritis: A Deep Learning Approach
-
Abstract Number: 0973
Assessing Musculoskeletal Health Needs of Underserved Patients & Community Members Using a Community Based Participatory Research Approach
-
Abstract Number: 0974
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
-
Abstract Number: 0975
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
-
Abstract Number: 0976
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
-
Abstract Number: 0977
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
-
Abstract Number: 0978
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
-
Abstract Number: 0979
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
-
Abstract Number: 0980
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
-
Abstract Number: 0981
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
-
Abstract Number: 0982
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0983
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
-
Abstract Number: 0984
Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
-
Abstract Number: 0985
S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
-
Abstract Number: 0986
Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)
-
Abstract Number: 0989
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
-
Abstract Number: 0990
KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
-
Abstract Number: 0991
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
-
Abstract Number: 0992
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
-
Abstract Number: 0993
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
-
Abstract Number: 0994
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
-
Abstract Number: 0995
Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
-
Abstract Number: 0996
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
-
Abstract Number: 0998
A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US
-
Abstract Number: 0999
Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus
-
Abstract Number: 1000
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
-
Abstract Number: 1001
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
-
Abstract Number: 1002
Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod
-
Abstract Number: 1003
Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
-
Abstract Number: 1004
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
-
Abstract Number: 1006
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
-
Abstract Number: 1007
Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
-
Abstract Number: 1008
Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics
-
Abstract Number: 1011
Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis
-
Abstract Number: 1012
Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study
-
Abstract Number: 1013
Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care
-
Abstract Number: 1014
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
-
Abstract Number: 1015
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
-
Abstract Number: 1016
Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
-
Abstract Number: 1018
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
-
Abstract Number: 1020
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
-
Abstract Number: 1021
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
-
Abstract Number: 1022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
-
Abstract Number: 1023
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
-
Abstract Number: 1024
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
-
Abstract Number: 1025
Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
-
Abstract Number: 1026
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
-
Abstract Number: 1027
Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
-
Abstract Number: 1028
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
-
Abstract Number: 1029
Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology
-
Abstract Number: 1030
Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis
-
Abstract Number: 1031
Foot Involvement in Psoriatic Arthritis- a Retrospective Study
-
Abstract Number: 1032
Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice
-
Abstract Number: 1033
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
-
Abstract Number: 1034
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
-
Abstract Number: 1035
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
-
Abstract Number: 1036
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
-
Abstract Number: 1037
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
-
Abstract Number: 1038
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
-
Abstract Number: 1039
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
-
Abstract Number: 1040
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
-
Abstract Number: 1041
Tofacitinib in Refractory Uveitis – an Observational Study
-
Abstract Number: 1042
Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
-
Abstract Number: 1043
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
-
Abstract Number: 1044
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
-
Abstract Number: 1045
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
-
Abstract Number: 1046
Scleroderma Heart Disease
-
Abstract Number: 1047
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
-
Abstract Number: 1048
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
-
Abstract Number: 1049
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
-
Abstract Number: 1050
Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis
-
Abstract Number: 1051
A Deep Neural Network Classifier to Identify Intrinsic Molecular Subsets of Systemic Sclerosis Using Histological Images
-
Abstract Number: 1052
Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
-
Abstract Number: 1053
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Resource Utilization and Gastrointestinal Tract Symptoms in Early Disease
-
Abstract Number: 1054
Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema
-
Abstract Number: 1055
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
-
Abstract Number: 1056
Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement
-
Abstract Number: 1057
Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
-
Abstract Number: 1058
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
-
Abstract Number: 1059
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
-
Abstract Number: 1060
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
-
Abstract Number: 1061
Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up
-
Abstract Number: 1062
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
-
Abstract Number: 1063
Assessment of Calcinosis in Portuguese Patients with Systemic Sclerosis – a Multicenter Study
-
Abstract Number: 1064
Test-retest Reliability for the Mawdsley Calcinosis Questionnaire for the Measurement of Calcinosis Burden in Patients with Systemic Sclerosis
-
Abstract Number: 1065
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
-
Abstract Number: 1066
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
-
Abstract Number: 1067
Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes
-
Abstract Number: 1068
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
-
Abstract Number: 1069
Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
-
Abstract Number: 1070
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
-
Abstract Number: 1071
Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
-
Abstract Number: 1072
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
-
Abstract Number: 1073
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
-
Abstract Number: 1074
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
-
Abstract Number: 1075
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
-
Abstract Number: 1076
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
-
Abstract Number: 1077
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
-
Abstract Number: 1078
Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
-
Abstract Number: 1079
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
-
Abstract Number: 1080
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
-
Abstract Number: 1081
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
-
Abstract Number: 1082
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
-
Abstract Number: 1084
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
-
Abstract Number: 1085
Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
-
Abstract Number: 1086
Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
-
Abstract Number: 1087
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
-
Abstract Number: 1088
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
-
Abstract Number: 1089
Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
-
Abstract Number: 1090
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
-
Abstract Number: 1091
IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
-
Abstract Number: 1092
Intrarenal Synthesis of Complement C3 Localized to Distinct Vascular Compartments in ANCA-associated Renal Vasculitis
-
Abstract Number: 1093
ANCA Associated Vasculitis: Online CME Improves Rheumatologists’ Knowledge and Confidence
-
Abstract Number: 1112
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
-
Abstract Number: 1113
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
-
Abstract Number: 1114
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
-
Abstract Number: 1115
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1118
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
-
Abstract Number: 1119
Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients
-
Abstract Number: 1120
Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues
-
Abstract Number: 1121
Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies
-
Abstract Number: 1122
Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease
-
Abstract Number: 1123
Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
-
Abstract Number: 1124
CD4+ Cytotoxic T Lymphocytes (CTL) Are Present in Sjögren’s Disease Minor Salivary Glands and Associate with Markers of Epithelial Cell Damage near Infiltrates
-
Abstract Number: 1125
Genomics of JAK-STAT Signaling in Venous Thromboembolism
-
Abstract Number: 1126
Functional NOTCH4 Variants Increase Notch Signaling and Susceptibility for Systemic Sclerosis
-
Abstract Number: 1127
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
-
Abstract Number: 1128
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
-
Abstract Number: 1130
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
-
Abstract Number: 1131
Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
-
Abstract Number: 1132
Interaction of LOC100507053, ADH1B, and ADH1C with Alcohol Consumption for Elevated Serum Urate Levels and Gout in People of European Ethnicity
-
Abstract Number: 1133
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1134
Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
-
Abstract Number: 1135
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
-
Abstract Number: 1136
Stratification of Systemic Lupus Erythematosus (SLE) Patients Based on the Molecular Patterns of Mouse Models
-
Abstract Number: 1137
MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy
-
Abstract Number: 1138
Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection and Common Molecular Signatures with Autoimmune Diseases
-
Abstract Number: 1139
Molecular Pathways Identified from Risk Alleles Identify Mechanistic Differences in Systemic Lupus Erythematosus Patients of East Asian and European Ancestry
-
Abstract Number: 1141
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
-
Abstract Number: 1142
The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
-
Abstract Number: 1143
Epigenome-wide Analysis of Osteoarthritis in the Multicenter Osteoarthritis Study
-
Abstract Number: 1144
Circulating miRNAs and Difficult-To-Treat Rheumatoid Arthritis: The Screening Study
-
Abstract Number: 1145
The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men
-
Abstract Number: 1146
Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis
-
Abstract Number: 1147
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
-
Abstract Number: 1148
GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA
-
Abstract Number: 1149
A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies
-
Abstract Number: 1150
Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems
-
Abstract Number: 1151
Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
-
Abstract Number: 1152
A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases
-
Abstract Number: 1153
Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
-
Abstract Number: 1154
Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
-
Abstract Number: 1155
Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
-
Abstract Number: 1156
Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
-
Abstract Number: 1157
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
-
Abstract Number: 1158
Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
-
Abstract Number: 1159
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
-
Abstract Number: 1160
Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
-
Abstract Number: 1161
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
-
Abstract Number: 1162
Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
-
Abstract Number: 1163
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
-
Abstract Number: 1164
Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
-
Abstract Number: 1165
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
-
Abstract Number: 1166
Scleroderma Fibroblasts Induce Alternative Macrophage Activation via an ERK1/2-dependent Mechanism
-
Abstract Number: 1167
Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages
-
Abstract Number: 1168
Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis
-
Abstract Number: 1169
Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration
-
Abstract Number: 1170
Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1
-
Abstract Number: 1171
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
-
Abstract Number: 1172
Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts
-
Abstract Number: 1173
Single-cell Multi-omic Analysis of a 3D Skin-Like Tissue Model Provides Insights into Molecular and Cellular Drivers of Systemic Sclerosis
-
Abstract Number: 1174
Cellular Immunotherapy for Systemic Sclerosis
-
Abstract Number: 1176
Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts
-
Abstract Number: 1177
Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis
-
Abstract Number: 1178
Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
-
Abstract Number: 1179
Single Cell RNA Sequencing Analysis of Cryopreserved versus Fresh Skin Biopsy Samples from Systemic Sclerosis Patients and Healthy Controls
-
Abstract Number: 1180
Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis
-
Abstract Number: 1181
Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis
-
Abstract Number: 1182
Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
-
Abstract Number: 1183
Functionally Distinct Fibroblast Populations in Systemic Sclerosis Skin Revealed by Explant Tissue Characterization and Single-cell RNAseq
-
Abstract Number: 1184
Intracellular Calcium Signals Regulate the Pro-fibrotic Phenotype of Scleroderma Fibroblasts via Calcium/calmodulin-dependent Kinase II
-
Abstract Number: 1185
Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis
-
Abstract Number: 1186
The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States
-
Abstract Number: 1187
Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
-
Abstract Number: 1188
Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
-
Abstract Number: 1189
Natural Language Processing of Chest CT Reports as a Novel Method of Identifying RA-ILD in Real-World Data
-
Abstract Number: 1190
Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)
-
Abstract Number: 1191
The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study
-
Abstract Number: 1192
Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample
-
Abstract Number: 1193
Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample
-
Abstract Number: 1194
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
-
Abstract Number: 1195
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
-
Abstract Number: 1196
Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
-
Abstract Number: 1197
Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank
-
Abstract Number: 1198
Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
-
Abstract Number: 1199
Validation of New Medication User Definitions in Single-Specialty EHR Data
-
Abstract Number: 1200
Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
-
Abstract Number: 1201
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
-
Abstract Number: 1202
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
-
Abstract Number: 1203
The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis
-
Abstract Number: 1204
An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in Rheumatoid Arthritis: A National, Matched Cohort Study from 2000 to 2019
-
Abstract Number: 1205
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
-
Abstract Number: 1206
Association Between Different Alcoholic Beverages and Serum Urate Level: A Cross-Sectional Study Using Large Medical Checkup Data
-
Abstract Number: 1207
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
-
Abstract Number: 1209
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
-
Abstract Number: 1210
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
-
Abstract Number: 1211
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
-
Abstract Number: 1212
Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
-
Abstract Number: 1213
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
-
Abstract Number: 1214
In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis
-
Abstract Number: 1215
Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing
-
Abstract Number: 1216
Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India
-
Abstract Number: 1217
The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions
-
Abstract Number: 1218
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
-
Abstract Number: 1219
Gender-Related Clinical Profile of Fibromyalgia Patients
-
Abstract Number: 1220
Autonomic Dysfunction in Sjogren’s Disease
-
Abstract Number: 1221
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
-
Abstract Number: 1222
Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military
-
Abstract Number: 1223
Autoimmune Thyroid Disease Associates with Hand Pain in Older Adults in the Third National Health and Nutrition Examination Survey
-
Abstract Number: 1224
‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK
-
Abstract Number: 1225
Sphygmomanometry for Fibromyalgia Detection in a Rheumatology Outpatient Clinic. a Cross-sectional Study
-
Abstract Number: 1227
Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia
-
Abstract Number: 1228
Distinctive Alterations in the Functional Anatomy of the Cerebral Cortex in Pain-sensitized Osteoarthritis and Fibromyalgia Patients
-
Abstract Number: 1229
Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept
-
Abstract Number: 1230
Diabetes Mellitus Nailfold Capillaroscopy Pattern: DM Pattern
-
Abstract Number: 1231
[68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease
-
Abstract Number: 1232
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
-
Abstract Number: 1233
Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
-
Abstract Number: 1234
Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
-
Abstract Number: 1235
Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis
-
Abstract Number: 1236
Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
-
Abstract Number: 1237
Assessment of Common Femoral Vein Intima-Media Thickness by Ultrasound in Behçet’s Disease: Comparative Study of Patients with or Without Vascular Involvement in a National Referral Center
-
Abstract Number: 1238
Can Thermal Imaging Help Clarify Joint Inflammation at Clinically Quiescent Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis?
-
Abstract Number: 1239
The Utility of Dual-Energy Computed Tomography in the Diagnosis of Gout
-
Abstract Number: 1240
A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis
-
Abstract Number: 1241
Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences
-
Abstract Number: 1242
Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis
-
Abstract Number: 1243
The Impact of MRI Slice Thickness on the Detection of Spinal Syndesmophytes in Axial Spondyloarthritis
-
Abstract Number: 1244
Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
-
Abstract Number: 1245
Imaging Use and Medication Management in Giant Cell Arteritis
-
Abstract Number: 1246
Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis
-
Abstract Number: 1247
Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
-
Abstract Number: 1248
A Retrospective Chart Review Examining How a Change in MRI Protocol Could Affect the Diagnosis of Axial Spondyloarthritis
-
Abstract Number: 1249
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
-
Abstract Number: 1250
Physiologic Adaptive Change of the Patellar and Achilles Tendons: Sensitivity to Change Detected by Computer Analysis of Sequential Static Images
-
Abstract Number: 1251
Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome
-
Abstract Number: 1252
Interrater Agreement of Hand Ultrasounds in Inflammatory Arthritis
-
Abstract Number: 1253
Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
-
Abstract Number: 1254
Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
-
Abstract Number: 1255
Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
-
Abstract Number: 1256
A Machine Learning Pipeline for Prediction of Bone Marrow Oedema Along the Sacroiliac Joints on Magnetic Resonance Imaging
-
Abstract Number: 1257
Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
-
Abstract Number: 1258
Development of International Consensus on a Standardized Image Acquisition Protocol for Diagnostic Evaluation of the Sacroiliac Joints by MRI – an ASAS-SPARTAN Collaboration
-
Abstract Number: 1259
Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
-
Abstract Number: 1260
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
-
Abstract Number: 1261
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
-
Abstract Number: 1262
Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
-
Abstract Number: 1263
Impact of Cardiovascular Risk on the Diagnostic Accuracy of the Ultrasound Halo Score for Giant Cell Arteritis
-
Abstract Number: 1264
Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
-
Abstract Number: 1265
External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic
-
Abstract Number: 1266
Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
-
Abstract Number: 1267
Accuracy of Financial Disclosures in American-Based Rheumatology Journals
-
Abstract Number: 1268
Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
-
Abstract Number: 1269
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
-
Abstract Number: 1270
MDHAQ/RAPID3 Is a Feasible Tool to Estimate High Comorbid Fatigue and Residual Fatigue in Rheumatoid Arthritis Patients
-
Abstract Number: 1271
Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry
-
Abstract Number: 1272
Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
-
Abstract Number: 1273
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
-
Abstract Number: 1274
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
-
Abstract Number: 1275
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
-
Abstract Number: 1276
Bone Density Imaging: Evaluation of Equipment and Process of Care Quality in US Veterans
-
Abstract Number: 1277
Improving Patient Appropriate Osteoporosis Screening with Dual Energy X-ray Absorptiometry Scans in an Academic Internal Medicine Practice
-
Abstract Number: 1278
ANA Testing Practices in the United States: A Population-Based Study Between 2000 and 2019
-
Abstract Number: 1279
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study
-
Abstract Number: 1280
Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
-
Abstract Number: 1281
Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
-
Abstract Number: 1282
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
-
Abstract Number: 1283
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
-
Abstract Number: 1284
Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines
-
Abstract Number: 1285
Joint Injection Workflow in Rheumatology – an Opportunity to Improve Efficiency and Physician Satisfaction
-
Abstract Number: 1286
Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center
-
Abstract Number: 1287
Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?
-
Abstract Number: 1288
How Often Do We Provide Relevant and Patient Centric Discharge Instructions in Rheumatology? A Single Academic Center Clinic Experience
-
Abstract Number: 1289
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
-
Abstract Number: 1291
Development and Pilot Implementation of a Predictive Model to Identify Visits Appropriate for Telehealth
-
Abstract Number: 1292
Telemedicine’s Impact on Radiologic Ordering in an Academic Rheumatology Practice During the COVID-19 Pandemic
-
Abstract Number: 1293
Is Virtual Care Here to Stay? : Rheumatology Patients’ Satisfaction in Early vs Late Pandemic
-
Abstract Number: 1294
Translation and Cross-cultural Adaptation of the CORS into Spanish
-
Abstract Number: 1295
Targeting Barriers That Prevent Contraception Counseling in an Academic Rheumatology Practice
-
Abstract Number: 1296
Impacting Demand Through Supply: An Evaluation of the Types of Pediatric Rheumatology Referrals at a Single Institution
-
Abstract Number: 1297
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
-
Abstract Number: 1298
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
-
Abstract Number: 1299
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
-
Abstract Number: 1300
Impact of Demographics and Health Literacy on Transition Readiness for Adolescents with Rheumatic Disease
-
Abstract Number: 1301
Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic
-
Abstract Number: 1302
Assessment of the Transition of Care from Pediatric to Adult Rheumatology in a Tertiary Center
-
Abstract Number: 1303
Planning Transition in Times of Transition: Is There a Virtual Pathway from Pediatric to Adult Care?
-
Abstract Number: 1304
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
-
Abstract Number: 1305
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1306
Improving Osteoporosis Screening in Individuals of Color
-
Abstract Number: 1307
Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
-
Abstract Number: 1308
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
-
Abstract Number: 1309
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
-
Abstract Number: 1310
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
-
Abstract Number: 1312
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
-
Abstract Number: 1313
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
-
Abstract Number: 1314
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
-
Abstract Number: 1315
Building Stronger Bones: Optimizing Osteoporosis Screening at a Primary Care Clinic
-
Abstract Number: 1316
A Cluster of Paget Disease of the Bone in Black or African American Patients in a Veteran Population
-
Abstract Number: 1317
The Epidemiology of Old versus Young Males Referred for BMD Assessment
-
Abstract Number: 1318
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
-
Abstract Number: 1319
Prognostic Utility of Metacarpal Bone Mineral Density Measurement in Patients with Recent-onset Arthritis by Assessment of Radiographic Progression at 2-year Follow Up
-
Abstract Number: 1321
Systemic Inflammatory-based Scores and Bone Turnover Ratio as Novel Diagnostic Tools for Chronic Nonbacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region in Adults
-
Abstract Number: 1322
Follow up of Incidentally Noted Vertebral Compression Fractures
-
Abstract Number: 1323
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
-
Abstract Number: 1324
Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study
-
Abstract Number: 1325
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
-
Abstract Number: 1326
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
-
Abstract Number: 1327
Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study
-
Abstract Number: 1328
CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
-
Abstract Number: 1329
Prevalence of Bone Fragility on DXA and CT in Patients with Obesity
-
Abstract Number: 1330
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
-
Abstract Number: 1331
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
-
Abstract Number: 1332
What Education Topics and Smartphone App Functions Do Rheumatology Patients Consider Important? Survey of Patients in a Community-Based Practice Network
-
Abstract Number: 1333
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
-
Abstract Number: 1334
Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)
-
Abstract Number: 1335
Artificial Intelligence–enabled Sentiment Analysis of Public Attitude Toward Pregnancy in Lupus Social Media Group
-
Abstract Number: 1336
Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
-
Abstract Number: 1337
Dietary Mineral Intake of an Inner-City Population and Its Impact on Disease Activity in Patients with SLE
-
Abstract Number: 1338
Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis
-
Abstract Number: 1339
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
-
Abstract Number: 1340
Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients
-
Abstract Number: 1341
Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
-
Abstract Number: 1342
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
-
Abstract Number: 1343
Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
-
Abstract Number: 1344
Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
-
Abstract Number: 1345
Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
-
Abstract Number: 1346
“Finally, I Can Do Something About It Myself”: A Process Evaluation of the Plants for Joints Lifestyle Intervention
-
Abstract Number: 1347
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
-
Abstract Number: 1348
We Asked Patients and Families: What Is the Job of a Pediatric Rheumatologist?
-
Abstract Number: 1349
Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
-
Abstract Number: 1350
A Prospective Study on Pain Associated with Injection of Needles: PAIN Study
-
Abstract Number: 1351
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
-
Abstract Number: 1352
Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
-
Abstract Number: 1353
Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
-
Abstract Number: 1354
Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
-
Abstract Number: 1355
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
-
Abstract Number: 1356
Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
-
Abstract Number: 1357
The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
-
Abstract Number: 1358
Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study
-
Abstract Number: 1359
Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia
-
Abstract Number: 1360
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
-
Abstract Number: 1361
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
-
Abstract Number: 1362
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
-
Abstract Number: 1363
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
-
Abstract Number: 1365
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
-
Abstract Number: 1366
Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma
-
Abstract Number: 1367
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
-
Abstract Number: 1368
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
-
Abstract Number: 1369
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
-
Abstract Number: 1370
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
-
Abstract Number: 1371
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
-
Abstract Number: 1372
Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients
-
Abstract Number: 1373
Increased Patient Contact May Mitigate Flares Among jSLE Patients
-
Abstract Number: 1374
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
-
Abstract Number: 1375
Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis
-
Abstract Number: 1376
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
-
Abstract Number: 1377
Mental Health Screening in Juvenile Myositis: Preliminary Analysis of a Multicenter Pilot Study
-
Abstract Number: 1378
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
-
Abstract Number: 1379
Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)
-
Abstract Number: 1380
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
-
Abstract Number: 1381
Health Related Quality of Life in Children with Systemic Lupus Erythematosus
-
Abstract Number: 1382
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
-
Abstract Number: 1383
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
-
Abstract Number: 1384
Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
-
Abstract Number: 1385
Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease
-
Abstract Number: 1386
The Association of Depression with Executive Function Skills and Health-Related Quality of Life in Youth with Systemic Lupus Erythematosus
-
Abstract Number: 1387
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
-
Abstract Number: 1388
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
-
Abstract Number: 1389
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
-
Abstract Number: 1390
Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort
-
Abstract Number: 1391
Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
-
Abstract Number: 1393
Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
-
Abstract Number: 1394
Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort
-
Abstract Number: 1395
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
-
Abstract Number: 1396
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
-
Abstract Number: 1397
The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis
-
Abstract Number: 1398
Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
-
Abstract Number: 1399
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
-
Abstract Number: 1400
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
-
Abstract Number: 1401
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
-
Abstract Number: 1402
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
-
Abstract Number: 1403
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
-
Abstract Number: 1404
Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data
-
Abstract Number: 1405
In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
-
Abstract Number: 1406
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
-
Abstract Number: 1407
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
-
Abstract Number: 1408
In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
-
Abstract Number: 1409
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
-
Abstract Number: 1410
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
-
Abstract Number: 1411
Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
-
Abstract Number: 1412
Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
-
Abstract Number: 1413
Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
-
Abstract Number: 1414
2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
-
Abstract Number: 1415
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
-
Abstract Number: 1416
Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
-
Abstract Number: 1417
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
-
Abstract Number: 1418
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
-
Abstract Number: 1419
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
-
Abstract Number: 1420
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
-
Abstract Number: 1422
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
-
Abstract Number: 1424
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
-
Abstract Number: 1425
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
-
Abstract Number: 1427
Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
-
Abstract Number: 1428
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
-
Abstract Number: 1429
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
-
Abstract Number: 1430
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
-
Abstract Number: 1431
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
-
Abstract Number: 1433
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
-
Abstract Number: 1434
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
-
Abstract Number: 1436
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
-
Abstract Number: 1438
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
-
Abstract Number: 1440
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
-
Abstract Number: 1441
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
-
Abstract Number: 1442
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
-
Abstract Number: 1443
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
-
Abstract Number: 1444
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
-
Abstract Number: 1445
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
-
Abstract Number: 1446
Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients
-
Abstract Number: 1447
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
-
Abstract Number: 1448
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
-
Abstract Number: 1449
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
-
Abstract Number: 1450
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
-
Abstract Number: 1451
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
-
Abstract Number: 1452
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
-
Abstract Number: 1453
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
-
Abstract Number: 1454
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
-
Abstract Number: 1455
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
-
Abstract Number: 1456
Latin-American Systemic Lupus Erythematosus Clusters
-
Abstract Number: 1457
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
-
Abstract Number: 1458
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
-
Abstract Number: 1459
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
-
Abstract Number: 1460
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
-
Abstract Number: 1461
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
-
Abstract Number: 1462
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
-
Abstract Number: 1463
Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
-
Abstract Number: 1464
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
-
Abstract Number: 1465
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
-
Abstract Number: 1466
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
-
Abstract Number: 1467
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
-
Abstract Number: 1468
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
-
Abstract Number: 1469
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1470
Work Disability and Function in Systematic Lupus Erythematosus (SLE): Results from a Mixed-Methods Exploratory Canadian Study
-
Abstract Number: 1471
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
-
Abstract Number: 1473
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
-
Abstract Number: 1474
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
-
Abstract Number: 1475
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1476
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
-
Abstract Number: 1477
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
-
Abstract Number: 1478
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
-
Abstract Number: 1479
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample
-
Abstract Number: 1480
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
-
Abstract Number: 1481
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
-
Abstract Number: 1482
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
-
Abstract Number: 1484
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
-
Abstract Number: 1485
Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
-
Abstract Number: 1486
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
-
Abstract Number: 1487
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
-
Abstract Number: 1488
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
-
Abstract Number: 1489
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
-
Abstract Number: 1490
High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
-
Abstract Number: 1491
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
-
Abstract Number: 1493
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
-
Abstract Number: 1494
Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years
-
Abstract Number: 1495
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
-
Abstract Number: 1496
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
-
Abstract Number: 1497
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
-
Abstract Number: 1498
The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
-
Abstract Number: 1499
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
-
Abstract Number: 1500
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
-
Abstract Number: 1501
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
-
Abstract Number: 1502
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
-
Abstract Number: 1504
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
-
Abstract Number: 1505
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
-
Abstract Number: 1506
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
-
Abstract Number: 1507
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
-
Abstract Number: 1508
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
-
Abstract Number: 1510
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
-
Abstract Number: 1511
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
-
Abstract Number: 1512
What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain
-
Abstract Number: 1514
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
-
Abstract Number: 1516
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
-
Abstract Number: 1517
Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
-
Abstract Number: 1518
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
-
Abstract Number: 1519
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
-
Abstract Number: 1520
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
-
Abstract Number: 1521
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
-
Abstract Number: 1522
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease
-
Abstract Number: 1523
Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement
-
Abstract Number: 1524
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
-
Abstract Number: 1525
Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
-
Abstract Number: 1526
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
-
Abstract Number: 1527
Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease
-
Abstract Number: 1528
Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
-
Abstract Number: 1529
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
-
Abstract Number: 1530
Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality
-
Abstract Number: 1531
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
-
Abstract Number: 1532
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
-
Abstract Number: 1533
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
-
Abstract Number: 1534
Blood Flow Assessment of Digital Arterioles and Capillaries in Systemic Sclerosis Patients Using Ultra-high Resolution Doppler Ultrasounds
-
Abstract Number: 1535
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
-
Abstract Number: 1536
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
-
Abstract Number: 1537
Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis
-
Abstract Number: 1538
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
-
Abstract Number: 1539
Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease
-
Abstract Number: 1541
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
-
Abstract Number: 1542
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
-
Abstract Number: 1543
Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
-
Abstract Number: 1544
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
-
Abstract Number: 1545
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
-
Abstract Number: 1546
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
-
Abstract Number: 1547
Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
-
Abstract Number: 1548
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
-
Abstract Number: 1549
Toward Safer Glucocorticoid Therapy
-
Abstract Number: 1550
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
-
Abstract Number: 1551
The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
-
Abstract Number: 1552
Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis
-
Abstract Number: 1553
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
-
Abstract Number: 1554
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
-
Abstract Number: 1555
Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
-
Abstract Number: 1556
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
-
Abstract Number: 1557
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
-
Abstract Number: 1558
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
-
Abstract Number: 1559
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
-
Abstract Number: 1560
Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease
-
Abstract Number: 1561
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
-
Abstract Number: 1562
Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
-
Abstract Number: 1563
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease
-
Abstract Number: 1564
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
-
Abstract Number: 1565
Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
-
Abstract Number: 1566
Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
-
Abstract Number: 1567
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
-
Abstract Number: 1568
Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS
-
Abstract Number: 1569
Lung Involvement in VEXAS Syndrome
-
Abstract Number: 1570
Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning
-
Abstract Number: 1571
Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
-
Abstract Number: 1572
CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
-
Abstract Number: 1573
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
-
Abstract Number: 1574
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
-
Abstract Number: 1575
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
-
Abstract Number: 1576
Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
-
Abstract Number: 1577
Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
-
Abstract Number: 1578
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
-
Abstract Number: 1675
Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial
-
Abstract Number: 1676
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
-
Abstract Number: 1677
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
-
Abstract Number: 1678
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
-
Abstract Number: 1679
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
-
Abstract Number: 1680
Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis
-
Abstract Number: 1681
Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts
-
Abstract Number: 1682
Peptidyl Arginine Deiminase Expression and Macrophage Polarization Following Stimulation with Citrullinated and Malondialdehyde-acetaldehyde Modified Fibrinogen
-
Abstract Number: 1683
Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages
-
Abstract Number: 1684
A Potent Inhibitor of PAD4 Suppresses Histone Citrullination in Vitro and in Vivo
-
Abstract Number: 1685
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
-
Abstract Number: 1686
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
-
Abstract Number: 1687
A Core Inflammation Program Conserved Across Human and Murine Neutrophils
-
Abstract Number: 1688
Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis
-
Abstract Number: 1689
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
-
Abstract Number: 1690
Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition
-
Abstract Number: 1691
Pentagalloyl Glucose Inhibits MSU-Induced Inflammation via Transforming Growth Factor-β-Activated Kinase 1 (TAK1)
-
Abstract Number: 1692
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
-
Abstract Number: 1693
Skin Pigmentation Association with Regulation of Cyclic-GMP-AMP Following Skin Exposure to UV Light
-
Abstract Number: 1694
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
-
Abstract Number: 1695
Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
-
Abstract Number: 1696
Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
-
Abstract Number: 1697
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
-
Abstract Number: 1698
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
-
Abstract Number: 1699
Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations
-
Abstract Number: 1700
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
-
Abstract Number: 1701
High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
-
Abstract Number: 1702
Targeting CD6-CD318 Axis with UMCD6 (anti-CD6) Enhances in Vivo Killing of Cancer Cells Through Direct Activation of NK Cells
-
Abstract Number: 1703
Potential Regulation of NK Cells by CD1c+ Dendritic Cells Through RIG-I/DDX60 Pathway Involved in Th17 Responses in Primary Sjögren Syndrome
-
Abstract Number: 1704
Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
-
Abstract Number: 1705
Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis
-
Abstract Number: 1706
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
-
Abstract Number: 1707
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE
-
Abstract Number: 1708
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
-
Abstract Number: 1709
Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
-
Abstract Number: 1710
CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
-
Abstract Number: 1711
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
-
Abstract Number: 1712
The Lymph Node Microenvironment in SLE Mice Is Altered and Impairs Egress of T Lymphocytes
-
Abstract Number: 1713
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
-
Abstract Number: 1714
The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE
-
Abstract Number: 1715
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
-
Abstract Number: 1716
The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice
-
Abstract Number: 1717
Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli
-
Abstract Number: 1718
Parenchymal INFγ Response Regulates Murine Lupus Nephritis
-
Abstract Number: 1719
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
-
Abstract Number: 1720
FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus
-
Abstract Number: 1721
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
-
Abstract Number: 1722
The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus
-
Abstract Number: 1723
CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model
-
Abstract Number: 1724
Perivascular Adipose Tissue Promotes Vascular Dysfunction in Murine Lupus
-
Abstract Number: 1725
Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice
-
Abstract Number: 1726
Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models
-
Abstract Number: 1727
BATF Represses BIM Expression to Sustain the T Cell Anergy Program
-
Abstract Number: 1729
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
-
Abstract Number: 1730
T Cell-Macrophage Interactions Play a Critical Role in a Mouse Model of Histidyl-tRNA Synthetase-Induced Myositis
-
Abstract Number: 1731
Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients
-
Abstract Number: 1732
Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
-
Abstract Number: 1733
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
-
Abstract Number: 1734
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
-
Abstract Number: 1735
Clonally Expanded Cytotoxic CD8+ T Cells Recognize Citrullinated Antigens in ACPA+ Rheumatoid Arthritis
-
Abstract Number: 1736
IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells
-
Abstract Number: 1737
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
-
Abstract Number: 1738
Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases
-
Abstract Number: 1739
Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis
-
Abstract Number: 1740
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
-
Abstract Number: 1741
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
-
Abstract Number: 1742
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
-
Abstract Number: 1743
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
-
Abstract Number: 1744
Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases
-
Abstract Number: 1745
Effects of Excess IL-18 in Mixed Inflammatory Environments
-
Abstract Number: 1746
Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
-
Abstract Number: 1747
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
-
Abstract Number: 1748
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
-
Abstract Number: 1749
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
-
Abstract Number: 1750
Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: A Population-based, Case-control Study
-
Abstract Number: 1751
Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management
-
Abstract Number: 1752
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
-
Abstract Number: 1753
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
-
Abstract Number: 1754
Association of Cognitive Impairment and Symptomatic Lower Extremity Osteoarthritis by Level of Physical Activity: Preliminary Data from the Johnston County Health Study
-
Abstract Number: 1755
Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology
-
Abstract Number: 1756
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
-
Abstract Number: 1757
The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years
-
Abstract Number: 1758
Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study
-
Abstract Number: 1759
Factors Affecting Success of Behavioral Interventions to Improve Physical Activity in Patients with Knee Osteoarthritis
-
Abstract Number: 1760
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
-
Abstract Number: 1761
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
-
Abstract Number: 1763
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
-
Abstract Number: 1764
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
-
Abstract Number: 1765
Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
-
Abstract Number: 1766
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
-
Abstract Number: 1767
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
-
Abstract Number: 1768
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
-
Abstract Number: 1769
Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
-
Abstract Number: 1770
Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review
-
Abstract Number: 1771
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
-
Abstract Number: 1773
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
-
Abstract Number: 1774
Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
-
Abstract Number: 1776
COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
-
Abstract Number: 1777
A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information
-
Abstract Number: 1778
More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
-
Abstract Number: 1779
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
-
Abstract Number: 1780
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
-
Abstract Number: 1781
Knee Pain Is Highly Associated with Ankle/Foot Pain, Arch Height, and Arch Flexibility: The Johnston County Osteoarthritis Project
-
Abstract Number: 1782
Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study
-
Abstract Number: 1783
Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
-
Abstract Number: 1784
Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study
-
Abstract Number: 1785
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
-
Abstract Number: 1786
Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study
-
Abstract Number: 1788
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
-
Abstract Number: 1789
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
-
Abstract Number: 1790
Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?
-
Abstract Number: 1791
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
-
Abstract Number: 1792
Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis
-
Abstract Number: 1793
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
-
Abstract Number: 1794
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
-
Abstract Number: 1795
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
-
Abstract Number: 1796
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
-
Abstract Number: 1797
Factors Driving Opioid Use in United States Veterans with Gout
-
Abstract Number: 1798
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
-
Abstract Number: 1799
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
-
Abstract Number: 1800
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
-
Abstract Number: 1801
High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
-
Abstract Number: 1802
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
-
Abstract Number: 1803
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
-
Abstract Number: 1804
Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
-
Abstract Number: 1805
Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares
-
Abstract Number: 1806
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
-
Abstract Number: 1808
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
-
Abstract Number: 1809
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
-
Abstract Number: 1810
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
-
Abstract Number: 1811
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
-
Abstract Number: 1812
Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
-
Abstract Number: 1813
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
-
Abstract Number: 1814
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
-
Abstract Number: 1815
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
-
Abstract Number: 1816
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
-
Abstract Number: 1817
Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
-
Abstract Number: 1818
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
-
Abstract Number: 1819
Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis
-
Abstract Number: 1820
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
-
Abstract Number: 1821
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
-
Abstract Number: 1822
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
-
Abstract Number: 1823
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
-
Abstract Number: 1824
eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
-
Abstract Number: 1825
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
-
Abstract Number: 1826
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
-
Abstract Number: 1827
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
-
Abstract Number: 1828
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
-
Abstract Number: 1829
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
-
Abstract Number: 1830
Characteristics of Arthritis in Familial Mediterranean Fever Patients
-
Abstract Number: 1831
Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)
-
Abstract Number: 1832
Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
-
Abstract Number: 1833
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
-
Abstract Number: 1834
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
-
Abstract Number: 1835
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
-
Abstract Number: 1836
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
-
Abstract Number: 1837
Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
-
Abstract Number: 1838
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
-
Abstract Number: 1839
Appendicitis Still a Challenge for FMF Patients?
-
Abstract Number: 1840
The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort
-
Abstract Number: 1841
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
-
Abstract Number: 1842
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
-
Abstract Number: 1843
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
-
Abstract Number: 1844
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
-
Abstract Number: 1845
Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study
-
Abstract Number: 1846
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
-
Abstract Number: 1848
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
-
Abstract Number: 1849
Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center
-
Abstract Number: 1850
Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
-
Abstract Number: 1851
Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients
-
Abstract Number: 1852
Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study
-
Abstract Number: 1853
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
-
Abstract Number: 1854
Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
-
Abstract Number: 1855
Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
-
Abstract Number: 1856
Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
-
Abstract Number: 1857
Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic
-
Abstract Number: 1858
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
-
Abstract Number: 1859
Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
-
Abstract Number: 1860
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
-
Abstract Number: 1861
Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones
-
Abstract Number: 1862
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
-
Abstract Number: 1863
Aromatase Inhibitor Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
-
Abstract Number: 1864
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
-
Abstract Number: 1865
Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria
-
Abstract Number: 1866
Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
-
Abstract Number: 1867
YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis
-
Abstract Number: 1868
B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
-
Abstract Number: 1869
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
-
Abstract Number: 1871
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
-
Abstract Number: 1872
Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
-
Abstract Number: 1873
Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
-
Abstract Number: 1874
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
-
Abstract Number: 1875
Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
-
Abstract Number: 1876
Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
-
Abstract Number: 1877
Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
-
Abstract Number: 1878
Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
-
Abstract Number: 1880
Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
-
Abstract Number: 1881
Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
-
Abstract Number: 1882
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
-
Abstract Number: 1883
Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
-
Abstract Number: 1884
Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
-
Abstract Number: 1885
Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
-
Abstract Number: 1886
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
-
Abstract Number: 1887
Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
-
Abstract Number: 1888
Novel Small Molecule Modulator of the gp130 Receptor Shows Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
-
Abstract Number: 1889
Investigating a Possible Bi-Directional Causal Relationship Between Gout and Osteoarthritis for the European Population: Two-Sampled Mendelian Randomization Analysis Study
-
Abstract Number: 1890
The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study
-
Abstract Number: 1891
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
-
Abstract Number: 1892
Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial
-
Abstract Number: 1893
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
-
Abstract Number: 1894
A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06)
-
Abstract Number: 1895
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
-
Abstract Number: 1896
Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study
-
Abstract Number: 1897
A Preliminary Estimate of Objectively Measured Sedentary Behavior in Knee Osteoarthritis
-
Abstract Number: 1898
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
-
Abstract Number: 1900
CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial
-
Abstract Number: 1901
What Does Radiographic Minimum JSW Actually Measure? Comparison of Radiographic and MRI Measures Using Data from the OAI
-
Abstract Number: 1902
Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials
-
Abstract Number: 1903
Does Pain Sensitization by Pressure Pain Thresholds and Temporal Summation Predict Persistent Pain in Persons with Hand OA?
-
Abstract Number: 1904
Is Treating Painful Hand Osteoarthritis with Hormone Replacement Therapy Feasible? Primary Results from a Randomised Controlled Trial in Post-menopausal Women
-
Abstract Number: 1905
Does Exercise Before Surgery Predict Trajectories of Physical Activity After Knee Replacement?
-
Abstract Number: 1906
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
-
Abstract Number: 1907
Strength Training Associates with Less Knee Osteoarthritis: Data from the Osteoarthritis Initiative
-
Abstract Number: 1909
Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol
-
Abstract Number: 1910
Evaluation of Dynamic Effects of Depressive Symptoms on Functional Outcomes in Knee Osteoarthritis
-
Abstract Number: 1911
Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning
-
Abstract Number: 1912
Associations of Nociceptive Dysfunction with Physical Activity in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
-
Abstract Number: 1913
The Association of Radiographic Chondrocalcinosis with Localized Structural Outcomes in Knee OA: The Multicenter Osteoarthritis Study
-
Abstract Number: 1914
Acoustic Classification of Early and Advanced Osteoarthritis of the Knee in Clinical Settings
-
Abstract Number: 1915
Development of an MRI-based Definition of Knee Osteoarthritis: Data from the Multicenter Osteoarthritis Study
-
Abstract Number: 1916
Defining Early-stage Knee Osteoarthritis: A Scoping Review
-
Abstract Number: 1917
A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial
-
Abstract Number: 1918
Neurobiological Mechanisms of a Remote-Delivered Mind-body Intervention for Knee Osteoarthritis
-
Abstract Number: 1919
Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
-
Abstract Number: 1920
Gait and Physical Activity Predictors of Knee Replacement: A Machine Learning Analysis in the Multicenter Osteoarthritis Study
-
Abstract Number: 1921
Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
-
Abstract Number: 1922
Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study
-
Abstract Number: 1923
Co-fluctuations of Knee Pain Between Knees in the Same Person: Data from the Osteoarthritis Initiative (OAI)
-
Abstract Number: 1924
Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
-
Abstract Number: 1925
Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series
-
Abstract Number: 1926
Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic
-
Abstract Number: 1927
Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
-
Abstract Number: 1928
Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
-
Abstract Number: 1929
Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
-
Abstract Number: 1930
Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America
-
Abstract Number: 1931
NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis
-
Abstract Number: 1932
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
-
Abstract Number: 1933
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
-
Abstract Number: 1934
Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
-
Abstract Number: 1935
Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
-
Abstract Number: 1936
A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype
-
Abstract Number: 1937
Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada
-
Abstract Number: 1938
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
-
Abstract Number: 1939
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
-
Abstract Number: 1940
Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers
-
Abstract Number: 1941
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
-
Abstract Number: 1942
Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags
-
Abstract Number: 1943
Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice
-
Abstract Number: 1944
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
-
Abstract Number: 1945
Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia
-
Abstract Number: 1946
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
-
Abstract Number: 1947
Medication Use in Childhood Sjogren Disease
-
Abstract Number: 1948
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
-
Abstract Number: 1949
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
-
Abstract Number: 1950
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
-
Abstract Number: 1951
Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
-
Abstract Number: 1952
Burden of Disease in Refractory Rheumatoid Arthritis
-
Abstract Number: 1953
Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
-
Abstract Number: 1954
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
-
Abstract Number: 1955
Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients
-
Abstract Number: 1956
Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study
-
Abstract Number: 1957
Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis
-
Abstract Number: 1959
Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
-
Abstract Number: 1960
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
-
Abstract Number: 1961
COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
-
Abstract Number: 1962
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
-
Abstract Number: 1963
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
-
Abstract Number: 1964
Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
-
Abstract Number: 1965
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
-
Abstract Number: 1966
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
-
Abstract Number: 1967
Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
-
Abstract Number: 1968
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
-
Abstract Number: 1969
The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis
-
Abstract Number: 1970
Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies
-
Abstract Number: 1971
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
-
Abstract Number: 1972
Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach
-
Abstract Number: 1973
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
-
Abstract Number: 1974
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
-
Abstract Number: 1975
Identifying MicroRNAs Associated with Neuropathic Pain in Patients with Rheumatoid Arthritis (RA)
-
Abstract Number: 1976
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
-
Abstract Number: 1977
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
-
Abstract Number: 1978
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
-
Abstract Number: 1979
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
-
Abstract Number: 1981
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
-
Abstract Number: 1982
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
-
Abstract Number: 1983
Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
-
Abstract Number: 1984
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
-
Abstract Number: 1986
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
-
Abstract Number: 1987
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
-
Abstract Number: 1989
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
-
Abstract Number: 1991
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
-
Abstract Number: 1992
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
-
Abstract Number: 1993
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
-
Abstract Number: 1994
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
-
Abstract Number: 1995
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
-
Abstract Number: 1996
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
-
Abstract Number: 1997
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
-
Abstract Number: 1998
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
-
Abstract Number: 1999
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
-
Abstract Number: 2000
Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis Patients: Follow up of the Pragmatic, Multicentre, Placebo-controlled GLORIA Trial
-
Abstract Number: 2001
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
-
Abstract Number: 2002
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
-
Abstract Number: 2003
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
-
Abstract Number: 2004
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
-
Abstract Number: 2006
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
-
Abstract Number: 2007
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
-
Abstract Number: 2009
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
-
Abstract Number: 2010
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
-
Abstract Number: 2011
More Meticulously Following Treat-to-target in RA Does Not Lead to Less Radiographic Progression: A Longitudinal Analysis in BIODAM
-
Abstract Number: 2012
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
-
Abstract Number: 2013
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
-
Abstract Number: 2014
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
-
Abstract Number: 2015
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
-
Abstract Number: 2016
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
-
Abstract Number: 2017
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
-
Abstract Number: 2018
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
-
Abstract Number: 2019
Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells
-
Abstract Number: 2020
Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
-
Abstract Number: 2021
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
-
Abstract Number: 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
-
Abstract Number: 2023
Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms
-
Abstract Number: 2024
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
-
Abstract Number: 2025
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
-
Abstract Number: 2026
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
-
Abstract Number: 2027
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
-
Abstract Number: 2028
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
-
Abstract Number: 2029
Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
-
Abstract Number: 2030
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
-
Abstract Number: 2031
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
-
Abstract Number: 2032
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
-
Abstract Number: 2033
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
-
Abstract Number: 2034
What Is the Best Initial Screening for Suspected Sjögren’s Disease?
-
Abstract Number: 2035
Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
-
Abstract Number: 2036
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
-
Abstract Number: 2037
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
-
Abstract Number: 2038
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
-
Abstract Number: 2039
The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
-
Abstract Number: 2040
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
-
Abstract Number: 2041
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
-
Abstract Number: 2042
Sjögren’s Disease and Mitochondrial Function
-
Abstract Number: 2043
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
-
Abstract Number: 2044
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
-
Abstract Number: 2045
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
-
Abstract Number: 2046
Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome
-
Abstract Number: 2047
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
-
Abstract Number: 2048
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
-
Abstract Number: 2049
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
-
Abstract Number: 2050
Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial
-
Abstract Number: 2051
Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction
-
Abstract Number: 2052
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
-
Abstract Number: 2053
Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
-
Abstract Number: 2054
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
-
Abstract Number: 2055
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
-
Abstract Number: 2056
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
-
Abstract Number: 2057
Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
-
Abstract Number: 2058
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2059
Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
-
Abstract Number: 2060
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
-
Abstract Number: 2061
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
-
Abstract Number: 2062
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
-
Abstract Number: 2063
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
-
Abstract Number: 2064
Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
-
Abstract Number: 2065
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
-
Abstract Number: 2066
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
-
Abstract Number: 2067
Predictors of Organ Damage Accrual by Domains
-
Abstract Number: 2068
All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
-
Abstract Number: 2069
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
-
Abstract Number: 2070
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
-
Abstract Number: 2072
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
-
Abstract Number: 2073
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
-
Abstract Number: 2074
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
-
Abstract Number: 2075
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
-
Abstract Number: 2076
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2077
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
-
Abstract Number: 2078
Mesangial Lupus Nephritis: Long Term Outcomes
-
Abstract Number: 2079
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
-
Abstract Number: 2080
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
-
Abstract Number: 2081
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
-
Abstract Number: 2082
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
-
Abstract Number: 2083
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
-
Abstract Number: 2084
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
-
Abstract Number: 2085
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
-
Abstract Number: 2086
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2087
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
-
Abstract Number: 2088
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
-
Abstract Number: 2089
The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
-
Abstract Number: 2091
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
-
Abstract Number: 2092
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
-
Abstract Number: 2094
Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)
-
Abstract Number: 2095
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
-
Abstract Number: 2096
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2097
Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis
-
Abstract Number: 2098
Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
-
Abstract Number: 2099
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
-
Abstract Number: 2100
Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus
-
Abstract Number: 2101
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
-
Abstract Number: 2103
Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus
-
Abstract Number: 2104
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
-
Abstract Number: 2105
Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
-
Abstract Number: 2106
Disparities of African American Mortality Trends in South Carolina Lupus Cohort
-
Abstract Number: 2107
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
-
Abstract Number: 2108
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
-
Abstract Number: 2110
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
-
Abstract Number: 2113
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
-
Abstract Number: 2114
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
-
Abstract Number: 2115
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
-
Abstract Number: 2116
Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
-
Abstract Number: 2120
Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
-
Abstract Number: 2121
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
-
Abstract Number: 2123
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
-
Abstract Number: 2124
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
-
Abstract Number: 2125
Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
-
Abstract Number: 2126
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
-
Abstract Number: 2127
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
-
Abstract Number: 2128
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
-
Abstract Number: 2129
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
-
Abstract Number: 2130
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
-
Abstract Number: 2131
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
-
Abstract Number: 2133
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
-
Abstract Number: 2134
Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
-
Abstract Number: 2135
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
-
Abstract Number: 2136
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
-
Abstract Number: 2137
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
-
Abstract Number: 2138
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
-
Abstract Number: 2140
Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
-
Abstract Number: 2142
Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
-
Abstract Number: 2143
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
-
Abstract Number: 2144
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
-
Abstract Number: 2145
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
-
Abstract Number: 2146
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
-
Abstract Number: 2147
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
-
Abstract Number: 2148
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
-
Abstract Number: 2149
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
-
Abstract Number: 2150
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
-
Abstract Number: 2151
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
-
Abstract Number: 2152
Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
-
Abstract Number: 2153
Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
-
Abstract Number: 2154
An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin
-
Abstract Number: 2155
Sclerodermoid Reaction Following Immune Checkpoint Inhibitor Therapy: A Case Series from MD Anderson Cancer Center
-
Abstract Number: 2156
Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study
-
Abstract Number: 2157
Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort
-
Abstract Number: 2158
A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort
-
Abstract Number: 2159
Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
-
Abstract Number: 2160
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
-
Abstract Number: 2161
Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features
-
Abstract Number: 2162
Systemic Sclerosis in Alaska Native/American Indian People in Alaska
-
Abstract Number: 2163
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
-
Abstract Number: 2164
Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
-
Abstract Number: 2165
Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
-
Abstract Number: 2166
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
-
Abstract Number: 2167
Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
-
Abstract Number: 2168
A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
-
Abstract Number: 2169
Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
-
Abstract Number: 2170
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
-
Abstract Number: 2171
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis
-
Abstract Number: 2172
Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis: 10 Years-Experience
-
Abstract Number: 2173
Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
-
Abstract Number: 2174
Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
-
Abstract Number: 2175
Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
-
Abstract Number: 2176
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
-
Abstract Number: 2177
Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History